Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Novo Nordisk (0TDD) Share Price & Analysis

11 Followers

0TDD Stock Chart & Stats

$40.82$0.00(0.00%)
At close: 4:30 PM GMT
$40$45Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$40.48 - $41.70
52-Week Range
$35.09 - $64.35
Previous Close
$40.82
Volume
N/A
Average Volume (3M)
107.36K
Market Cap
$178.86B
Enterprise Value
$181.06B
Total Cash (Recent Filing)
$49.18B
Total Debt (Recent Filing)
$134.48B
Price to Earnings (P/E)
10.8
Beta
0.86
Next Earnings
Feb 03, 2027 (Est.)
EPS Estimate
0.66
Next Dividend Ex-Date
N/A
Dividend Yield
4.48%

Bulls Say, Bears Say

Bulls Say

GLP-1 Market Position And Growth

Novo combines broad patient reach with leading GLP-1 market share and continuing obesity growth. Expanding adoption across diabetes and obesity strengthens commercial scale, supports recurring chronic-care demand, and reinforces the company’s ability to extend its position through new oral and injectable offerings.

Product Innovation And Pipeline

Clinical progress across CagriSema, oral amycretin, and multiple early-stage programs provides a broad source of potential future products. This pipeline depth can support portfolio renewal, expand treatment options, and reduce reliance on any single commercial therapy over the next several years.

High Profitability And Balance Sheet Strength

Very high profitability and a substantial equity base give Novo meaningful capacity to fund research, manufacturing expansion, launches, and shareholder returns. Although leverage has risen, the balance sheet remains manageable, preserving financial flexibility as the company invests behind its growth platforms.

Bears Say

Pricing And Payer Pressure

Persistent price erosion can reduce the net revenue and profit contribution of Novo’s largest therapies even when prescription volumes rise. Reimbursement negotiations, PBM pressure, and employer resistance to obesity coverage may therefore constrain margin durability and limit the value of category expansion.

Loss Of Exclusivity And China Headwinds

Loss of exclusivity threatens realized prices and market economics in affected regions, while China’s ongoing headwind adds another structural drag. These pressures can persist beyond a single quarter, requiring stronger volume growth and successful launches to offset erosion across established products.

Weakening Free-Cash Conversion

Novo generates substantial operating cash, but declining free cash flow and weaker conversion from earnings reduce the quality and flexibility of that cash generation. If the pattern persists, less internally generated funding may be available for pipeline investment, capacity expansion, and capital returns.

Novo Nordisk News

0TDD FAQ

What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest share price was $35.09 and its highest was $64.35 in the past 12 months.
What is Novo Nordisk’s market cap?
Novo Nordisk’s market cap is $178.86B.
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s next earnings report is estimated for Feb 03, 2027 (not yet confirmed), which is in 81 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on Nov 04, 2026. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.731 by $0.139.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Undervalued.
Does Novo Nordisk pay dividends?
Novo Nordisk does not currently pay dividends.
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is 0.66.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of $0.87 in its last earnings report, beating expectations of $0.731. Following the earnings report the stock price went up 5.941%.
Which hedge fund is a major shareholder of Novo Nordisk?
Hedge funds hold Novo Nordisk shares: the largest hedge-fund position in Novo Nordisk is 1,565,361,635 shares, and hedge funds increased their holdings by 21.3M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology